These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17062374)

  • 21. Effects of buspirone on dopaminergic supersensitivity.
    Queiroz CM; Frussa-Filho R
    Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic administration of haloperidol during development: later psychopharmacological responses to apomorphine and arecoline.
    Shalaby IA; Spear LP
    Pharmacol Biochem Behav; 1980 Nov; 13(5):685-90. PubMed ID: 7192405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioural and biochemical effects in the adult rat after prolonged postnatal administration of clozapine.
    Cuomo V; Cagiano R; Mocchetti I; Coen E; Cattabeni F; Racagni G
    Psychopharmacology (Berl); 1983; 81(3):239-43. PubMed ID: 6417713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of acute treatment with dopaminergic drugs on open field behavior of adult monkeys treated with lead during the first year postpartum.
    Ferguson SA; Felipa HN; Bowman RE
    Neurotoxicol Teratol; 1996; 18(2):181-8. PubMed ID: 8709930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
    Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of apomorphine and haloperidol: effects on locomotion and other behaviour in the marmoset.
    Scraggs PR; Baker HF; Ridley RM
    Psychopharmacology (Berl); 1979; 66(1):41-3. PubMed ID: 120540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice.
    Fukushiro DF; Alvarez Jdo N; Tatsu JA; de Castro JP; Chinen CC; Frussa-Filho R
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):867-72. PubMed ID: 17368685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
    Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
    Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of apomorphine administration on locomotor activity of control and experimental rats withdrawn from long-term haloperidol treatment.
    Bernardi MM; Palermo-Neto J
    Gen Pharmacol; 1983; 14(5):545-7. PubMed ID: 6685669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
    Lipska BK; Weinberger DR
    Neuropsychopharmacology; 1994 May; 10(3):199-205. PubMed ID: 7916917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of apomorphine administration on rearing activity of control and experimental rats withdrawn from long-term haloperidol treatment.
    Bernardi MM; Palermo-Neto J
    Gen Pharmacol; 1984; 15(4):363-5. PubMed ID: 6541605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-D-aspartate on motor activity in mice.
    Giménez-Llort L; Martínez E; Ferré S
    Eur J Pharmacol; 1995 Mar; 275(2):171-7. PubMed ID: 7796852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral responses to methylphenidate and apomorphine in rats exposed neonatally to bisphenol-A.
    Kiguchi M; Fujita S; Lee J; Shimizu N; Koshikawa N
    J Oral Sci; 2007 Dec; 49(4):311-8. PubMed ID: 18195515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
    Quinn LP; Stean TO; Chapman H; Brown M; Vidgeon-Hart M; Upton N; Billinton A; Virley DJ
    J Neurosci Methods; 2006 Sep; 156(1-2):218-27. PubMed ID: 16626808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment.
    Smith RC; Davis JM
    Psychopharmacol Commun; 1975; 1(3):285-93. PubMed ID: 1241453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different behavioural patterns induced by the dopamine agonist apomorphine analysed by multivariate statistics.
    Ståhle L; Ungerstedt U
    Pharmacol Biochem Behav; 1986 Feb; 24(2):291-8. PubMed ID: 3952117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.
    De Souza IE; Dawson NM; Clifford JJ; Waddington JL; Meredith GE
    Psychopharmacology (Berl); 2003 Aug; 169(1):28-34. PubMed ID: 12830366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The behavioral and neurochemical changes in rats caused by the subchronic administration of haloperidol].
    Shevchenko TP; Tolpyshev BA; Zban' LN
    Eksp Klin Farmakol; 1993; 56(3):15-7. PubMed ID: 8219980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations.
    LeDuc PA; Mittleman G
    Psychopharmacology (Berl); 1993; 110(4):427-36. PubMed ID: 7870913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.